Mainz Biomed, a company that specializes in developing molecular genetic diagnostic solutions for life-threatening conditions, has created ColoAlert®, an innovative product that addresses the need for easier and more accessible cancer screenings for quick detection and treatment of colorectal cancer. This non-invasive and user-friendly test aims to make colorectal cancer screening fast, simple and precise. The company has recently formed a partnership with Liquid Biosciences, aiming to leverage the capabilities of AI in developing an advanced colorectal screening test.
Category
🗞
NewsTranscript
00:00 (upbeat music)
00:02 Mainz Biomed, a company that specializes
00:04 in developing molecular genetic diagnostic solutions
00:07 for life-threatening conditions, has created Coloaler,
00:09 an innovative product that addresses the need
00:11 for easier and more accessible cancer screenings
00:14 for quick detection and treatment of colorectal cancer.
00:17 This non-invasive and user-friendly test
00:19 aims to make colorectal cancer screening fast,
00:22 simple, and precise.
00:23 The company has recently formed a partnership
00:25 with Liquid Biosciences, aiming to leverage
00:27 the capabilities of AI in developing
00:29 an advanced colorectal screening test.
00:32 Its partnership with Liquid Biosciences
00:34 will help expand the company's existing
00:36 cutting-edge products.
00:37 Recently, Mainz Biomed conducted a multi-year center
00:41 international clinic trial in Germany and Norway
00:44 to evaluate the effectiveness of incorporating
00:46 mRNA biomarkers into Coloaler, their leading product
00:49 for colorectal cancer screening, also known as CRC.
00:53 The study yielded impressive findings,
00:54 demonstrating a high sensitivity of 94.4
00:58 and specificity of 97.5 for detecting CRC.
01:02 Additionally, the screening test showed a sensitivity
01:04 of 80% and specificity of 95.2%
01:08 and detecting precursor lesions,
01:09 including advanced adenomas that may develop into CRC.
01:13 These results were nothing short of groundbreaking
01:15 for the company.
01:16 The partnership with Liquid Biosciences
01:18 has the potential to move the needle forward,
01:20 as Liquid Biosciences has a history of using AI
01:23 to advance similar technologies.
01:25 Liquid Biosciences had made a significant impact
01:27 on the life sciences industry
01:29 with its eMERGE BioAnalyticals platforms.
01:32 This platform has been utilized in more than 240 projects
01:35 for prominent pharmaceutical companies
01:37 and emerging therapeutic and diagnostic firms.
01:40 It plays a crucial role in various areas,
01:42 such as biomarker discovery, clinical trial screening,
01:45 and post-FDA approval services,
01:47 including patent treatment section
01:49 and optimal dosing regimens.
01:51 Guido Bacler, who is the chief executive officer
01:53 of Mines Biomed said,
01:55 "As artificial intelligence continues to disrupt
01:57 every aspect of the healthcare sector,
01:59 we are excited to establish a robust partnership
02:01 with a genuine leader in the field
02:03 as we head into the final development state
02:05 of our next generation CRC screening test."
02:08 He continued to say,
02:09 "We look forward to continuing
02:10 our highly productive partnership
02:12 with Liquid Biosciences team,
02:14 as we execute on our mission to bring the most effective,
02:16 self-administered cancer detection products to the market."
02:20 Liquid Biosciences reports what makes eMERGE truly stand out
02:23 from other AI and machine learning solutions
02:26 is its exceptional computational speed
02:28 and ability to handle a vast amount of variables.
02:32 It operates without making any assumptions or constraints,
02:34 allowing for an unbiased and scalable approach.
02:37 The platform's transparency and ability
02:39 to generate algorithms from its complex data
02:42 without prior assumptions,
02:43 enable the identification of variables
02:45 that may have low expression,
02:47 but hold functional significance
02:48 due to the intricate interactions inheritance
02:51 in complex biological systems.
02:53 Patrick Lilly, who is the CEO of Liquid Biosciences said,
02:56 "We are excited to extend our relationship
02:58 with Minds Biomed into a formal partnership
03:01 as we take great pride in working with companies
03:03 who represent disruptive innovation
03:05 that will impact disease prevention and treatment."
03:08 Patrick continued to mention
03:09 that the work Minds Biomed is doing
03:11 will be crucial to saving lives
03:13 from a disease where mortality is driven by late detection.
03:16 As such, we are very pleased to have the opportunity
03:18 to play an integral role in helping it develop
03:21 the next generation of its pioneering products.
03:24 The partnership with Liquid Biosciences
03:26 comes after a string of previous partnerships
03:28 with other industry leaders like Zoller Kepper
03:30 and Arts and Leisure's labor, Dr. Bollman.
03:32 Through the partnership between Minds Biomed
03:35 and German company Zoller Kepper,
03:37 accessibility to colo alert test has been greatly enhanced
03:40 for both patients and healthcare providers.
03:42 All of Zoller Kepper's over 2,500 employees
03:45 can now easily request a test
03:47 through Biomed's online portal
03:49 and have it delivered to their doorstep.
03:51 Once the sample is received and processed,
03:53 the employee can access their confidential test results
03:56 through the portal.
03:57 The portal also provides an explanation of the results
03:59 to ensure that the employee understands them.
04:01 And if the employee has given consent
04:03 for their physician to be notified,
04:05 the doctor can directly follow up with them
04:06 based on the test results.
04:08 With colorectal cancer
04:09 being the third most prevalent form of cancer
04:11 and a troubling trend of this cancer
04:13 affecting more and more young people,
04:15 the need for biotech companies
04:16 to innovate detection and treatment
04:18 could not be understated.
04:20 Minds Biomed's commitment
04:21 to pushing the boundaries of diagnostic technology,
04:24 increasing accessibility, and its growth trajectory
04:27 seems to be making a force to be reckoned with
04:29 in the industry, setting it apart
04:31 from all of its competitors.
04:32 (upbeat music)